The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
March 2023 Scinv’s Sprinter trial analysis. It was truly comedy gold
Scinv_temp
Posted in: SNG
Posts: 1,028
Price: 7.50
No Opinion
RE: BARDA detailed interests
31 Mar 2023 15:22
Deaths:
Day 7
Sng001 4, placebo 0
Day 14,
Sng001 9, placebo 7
Day 21
Sng001 12, placebo 9
Day 28
Sng001 14, placebo 14
Day 35
Sng001 14, placebo 17.
Total Deaths
Sng001 53, placebo 47
TommyD_19
Posts: 3,083
Price: 7.50
No Opinion
RE: BARDA detailed interests
31 Mar 2023 15:37
Scinv
14 died on drug and 17 on placebo
You’re not meant to add up each week for a grand total you muppet
Wow
The muppet who added up Sprinter trial data to get the wrong calculations for patient numbers being ventilated has returned to tell us all about the science.
When I say returned I obviously mean reusing an old account.
Https://www.synairgen.com/science/programmes
Pre-clinical research conducted by Synairgen of IFN-β (at concentrations readily achievable following inhaled delivery of SNG001) shows the inhibition of a broad range of viruses in cell-based assays including:
viruses which cause seasonal cold (e.g., RSV, Rhinovirus) and flu infections
highly pathogenic viruses such as H5N1 ‘bird flu’ and Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
Of course when it comes to directors faith, you could also say they had many opportunities after the crash when the share recovered to mid 30’s to sell shares 20 times or more above their face value but chose not to.
There are many forms of faith but probably fewer on this board amongst some.
Given the enormous possibility for ongoing trials through talks with platforms here and in the U.S. plus the interactions with parties on moving the drug forward in a partnership deal. The outcomes of trial reviews and presentations of positive results.
I wonder how many opportunities would have been available for directors to deal without contravening the regulatory guidelines on insider information
If only vaccines hadn’t been invented
If only governments hadn’t stopped funding trials
If only all drug trials were 100% guaranteed
If only we’d had 1600 patients in a trial we couldn’t afford
yadda yadda yadda
Yawn
Dundee university having referenced MX1 as a potential biomarker for severity of disease ties in nicely with out COPD findings
https://erj.ersjournals.com/content/54/suppl_63/OA263
Antiviral biomarkers are upregulated in sputum cells following administration of inhaled interferon beta to COPD patients
Sophie Reynolds, Kerry Lunn, Rona Beegan, Victoria Tear, Phillip D Monk
“Results: Inhaled IFN-β was well tolerated. All antiviral biomarkers were significantly upregulated 24hrs post dose.
Fold upregulation in Mx1 and OAS1 gene expression was similar to that seen at the same dose in stable asthmatics.
Conclusions: Antiviral biomarkers were significantly upregulated in the lungs of COPD patients following the administration of inhaled IFN-β, supporting the proposed mechanism-of-action as a treatment for virus-induced exacerbations”
Interesting study given the collaboration between these groups Synairgen, Southampton, Universal, Dundee (lead investigator J Chalmers)
New study
Accepted November 23, 2023
Published online March 7, 2024.
https://erj.ersjournals.com/content/63/3/2300787
Corresponding author: James D. Chalmers (j.chalmers@dundee.ac.uk)
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection
This included 101 IFN-I signature proteins that were increased in abundance ……including MX1 and MX2 (figure 1h; supplementary figure S2). MX1 in particular was highly abundant with a pronounced and robust increase in COVID-19
This divergence suggests the potential for using MX1 as a marker for IFN-I activity, as described previously [46], whereby levels of MX1 could be measured in blood using a lateral flow test [47]. This could theoretically be used to stratify critically ill patients lacking an IFN-I response who could potentially benefit from IFN-β treatment during acute severe viral infection.
Who’d have thought ?
Mice and rats have long served as the preferred species for biomedical research animal models due to their anatomical, physiological, and genetic similarity to humans
Research on mice has been vital to the discovery of key features of both innate and adaptive immune responses;
For example, the first descriptions of the major T cell receptor, and antibody synthesis were derived from experiments performed on mice.
I guess there are two camps here. Those who believe the company are working hard to deliver new trials and when they have completed that work, they will update the market with news and dates.
Those who think the company are useless and will never deliver or at best deliver something pretty uninspiring.
The company could waste their time appeasing the later but quite honestly we saw what happened with the new years update from RM in 2023. Those people just treated it with derision and wouldn’t be any happier now with a “making good progress” statement.
I’ve been given a timeframe in the last update and I’m patient enough to wait. Hand holding along the way is a fairly pointless activity for the board.
Very interesting in the French study
The treatment with inhaled IFN was accompanied by a decrease in serum CRP in all patients. Serum IL-6 also decreased except for patient 4, and was fluctuating in patient 1, according to the use of continuous venous dialysis. At the same time, the white blood cell count normalized, with an increase in lymphocyte count